Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Medincell SA

MEDCL.PA ✗ NOT COMPLIANT ☆ Track — members

Euronext Paris · Healthcare · Pharmaceuticals ·

France Small Cap Analyst: BUY

Last Close

$27.88

▼ -1.63%

Market Cap $997.64M · Vol 56.79K

Key Metrics

P/E Ratio

N/A

FWD: 31.51

Market Cap

$997.64M

Small Cap

Div Yield

N/A

Annual dividend

EPS Growth

+187.03%

YoY

RSI (14)

35.91

Momentum

Beta

1.09

vs Market

52W High

$45.91

39.08% below

52W Low

$19.15

44.03% above

Volume

56.79K

Avg 67.43K

P/B

264.10

Price-to-book

ROE

470.38%

Return on equity

Free Float

66.01%

Public shares

Shariah Compliance8 STANDARDS

✗ Medincell SA (MEDCL.PA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MEDCL.PA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.63%

-8.78%

-16.09%

-3.68%

YTD

-4.37%

+46.50%

+290.38%

+165.71%

Financials & Valuation

TTM · Annual

Total Revenue	$22.55M
Net Income	$-36,142,783.00
Revenue Growth (YoY)	-52.91%
Gross Margin	100.00%
Operating Margin	-106.28%
Net Profit Margin	-160.30%
ROE	470.38%
ROA · ROIC	-31.59% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	31.51
PEG Ratio	N/A
P/S	38.54
P/B	264.10
P/FCF	N/A
EPS Growth	+187.03%
Outstanding Shares	35.91M

Technical Indicators

50-Day SMA	$30.39
200-Day SMA	$29.89
RSI (14)	35.91
Beta	1.09
52-Week High	$45.91
52-Week Low	$19.15

Volume Today	56.79K
Avg Daily Volume (30D)	67.43K
Relative Volume	0.84x
Volatility (10D)	31.40
Volatility (30D)	30.87
Free Float	66.01%

Analyst Consensus

BUY

Current Price $27.88

Mean Target $38.91

52W Low$19.15 52W High$45.91

Current

Target

$19.15 $45.91

Current Analyst target

+39.55% upside potential · 6 analysts

Identifiers

ExchangeEuronext Paris

FIGIBBG00J2HMMW0

ISINFR0004065605

CountryFrance

Sub-IndustryPharmaceuticals (NEC)

Earnings DateDec 8, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.